UTHRHealthcare · Drug Manufacturers - Specialty & GenericThe 14 Wall Street analysts covering United Therapeutics Corp. hold a median 12-month price target of $685 — +37.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores United Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (37): Analysts have, on balance, been cutting their forecasts.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on UTHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +37.8% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $704 → $677 |
| 23 July 2026 | JP Morgan | Maintains | Overweight | $685 → $687 |
| 23 July 2026 | JP Morgan | Maintains | Overweight | — |
| 10 July 2026 | B of A Securities | Maintains | Neutral | — |
| 10 July 2026 | B of A Securities | Maintains | Neutral | $620 → $613 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $701 → $704 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 May 2026 | RBC Capital | Maintains | Outperform | — |
| 7 May 2026 | Wells Fargo | Upgrade | Overweight | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 31 Mar 2026 | B of A Securities | Maintains | Neutral | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 23 Mar 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 Mar 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Mar 2026 | UBS | Maintains | Buy | — |
| 26 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Feb 2026 | Oppenheimer | Maintains | Outperform | — |
| 26 Feb 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UTHR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, United Therapeutics Corp. returned +22.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 19% of US stocks
Cheaper than 30% of US stocks
Cheaper than 29% of US stocks
Higher than 24% of US stocks
Higher than 45% of US stocks
Higher than 95% of US stocks
Higher than 93% of US stocks
Higher than 95% of US stocks
Higher than 80% of US stocks
Higher than 94% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
United Therapeutics Corp. has a market value of $21.3B and an enterprise value of $18.7B.
Revenue in the twelve months to 30 June 2026: $3.2B. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: $1.3B, a 41.6% net margin.
Diluted earnings per share, trailing twelve months: $27.95.
Free cash flow in the twelve months to 30 June 2026: $1.1B.
United Therapeutics Corp. spent $2.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 17.8×; forward P/E: 16.6× — the forward figure prices analyst consensus estimates, not reported earnings.
United Therapeutics Corp. employs 1,400 people — $2.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own United Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
United Therapeutics Corporation presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The article provides a transcript of the company's presentation at the event.
Why it matters — A UTHR watcher would follow this transcript for direct commentary from company leadership at a major healthcare conference.
United Therapeutics Corporation presented at the Wells Fargo 21st Annual Healthcare Conference, and a transcript of the presentation was published on Seeking Alpha. The item reports on the company's participation at the conference event.
Why it matters — A UTHR watcher would care because a transcript from a major healthcare conference may provide insight into the company's business and strategy as presented to investors and analysts.
United Therapeutics announced it will use the remainder of its previously announced $2 billion share repurchase authorization by entering into an Accelerated Share Repurchase (ASR) agreement with Citibank to buy back approximately $477.6 million of its common stock.
Why it matters — The repurchase completes the company's planned $2 billion buyback authorization, which returns capital to shareholders and may reduce outstanding shares.
United Therapeutics (UTHR) reported earnings 30 days ago, and its stock has declined 8% since then. The piece questions whether the stock can rebound following the recent earnings report.
Why it matters — A UTHR watcher would want to track the stock's post-earnings slide and assess whether the company can recover from the recent decline.
The FDA has accepted United Therapeutics' supplemental New Drug Application for Tyvaso as a label expansion in idiopathic pulmonary fibrosis. The application is supported by TETON study data showing improved lung function and reduced clinical worsening.
Why it matters — A UTHR watcher would care because FDA acceptance of the Tyvaso sNDA for IPF represents potential label expansion and a new regulatory milestone for the drug.
The 14 Wall Street analysts covering United Therapeutics Corp. have a median 12-month price target of $685, with estimates ranging from $515 to $725. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering United Therapeutics Corp., 11 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks United Therapeutics Corp. 82 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, United Therapeutics Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +37.8% from the last close, and Ticker Nerd's factor model ranks United Therapeutics Corp. 82 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering United Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $515 to $725 over the next 12 months.
United Therapeutics Corp. returned +22.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
United Therapeutics Corp. is a biotechnology company focused on developing and commercializing medicines for patients with serious, chronic, and life-threatening diseases.
The most recent item we track (Seeking Alpha, 9 Sept 2026): "United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript". United Therapeutics Corporation presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The article provides a transcript of the company's presentation at the event.
United Therapeutics Corp. is a biotechnology company focused on developing and commercializing medicines for patients with serious, chronic, and life-threatening diseases. Its portfolio centers on therapies for pulmonary arterial hypertension, including inhaled, oral, and injectable treatments built around treprostinil, as well as additional products for selected rare and severe conditions. The company also markets delivery systems and related treatment options that support ongoing care in specialized respiratory and cardiovascular settings. United Therapeutics Corp. serves patients, clinicians, and healthcare providers across the United States and international markets, with a business model centered on specialty pharmaceuticals and disease-specific therapies. Headquartered in Silver Spring, Maryland, United Therapeutics Corp. operates as a biotechnology company with a strong focus on addressing complex unmet medical needs through commercial products and targeted treatment platforms.
CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. · 1,400 employees · United States · https://www.unither.com
